Nvidia's Stock Dips 0.84% on Record $28.34B Turnover as China Sales Resume and Groq Chip Launch Spark Investor Frenzy

Market Snapshot

On March 18, 2026, Nvidia (NVDA) closed with a 0.84% decline, trading at $181.93, marking a reversal from its premarket gains. The stock led the market in trading volume, with $28.34 billion in turnover, underscoring heightened investor activity amid regulatory and strategic developments. Despite a premarket rally driven by China-related news, the day’s closing price reflected mixed sentiment, as the broader market digested implications of Nvidia’s renewed China market engagement and broader financial metrics.

Key Drivers

The resumption of H200 AI chip sales in China emerged as a pivotal catalyst for Nvidia’s stock performance. After months of regulatory uncertainty, the company secured approvals from both the U.S. and Chinese governments to resume shipments of its second-most powerful AI chip. CEO Jensen Huang confirmed that production had restarted following purchase orders from multiple Chinese customers, including tech giants like Alibaba and Tencent. This approval resolved a critical bottleneck that had previously restricted China’s access to advanced U.S. AI technology, a market that once contributed at least 20% of Nvidia’s data center revenue before export controls forced a $5.5 billion charge. The regulatory breakthrough signals a strategic shift, as China’s market re-entry could unlock significant growth potential for Nvidia, particularly as Chinese firms ramp up AI infrastructure investments.

Complementing the H200 approval, Nvidia is developing a China-specific variant of its Groq AI chip tailored for inference workloads. This move addresses a competitive challenge, as Chinese firms like Baidu already produce inference chips, a segment where Nvidia faces steeper competition. The Groq chip, expected in May, will pair with the Vera Rubin line for Chinese customers, ensuring compatibility with existing systems without downgrading performance. This adaptation highlights Nvidia’s focus on maintaining a foothold in the inference market, where demand is surging due to the rise of agentic AI systems requiring faster processing. The strategic alignment of Groq with Vera Rubin chips underscores Nvidia’s broader effort to diversify its product offerings in China while navigating regulatory constraints.

Financial metrics further contextualize the stock’s performance. Nvidia’s market cap remains robust at $4.42 trillion, with trailing revenue of $215.94 billion and a profit margin of 55.60%. Q4 FY26 results showed $68.13 billion in revenue and $39.55 billion in earnings, reflecting strong operational leverage. Analysts have maintained a “Strong Buy” consensus, with an average price target of $274.46, implying over 50% upside from current levels. However, the stock’s 0.84% decline suggests investor caution, as the resumption of China sales faces practical hurdles, including U.S. revenue-sharing requirements (25% of H200 sales) and Chinese regulatory scrutiny of foreign technology.

The regulatory landscape remains a double-edged sword. While the U.S. Trump administration’s December 2025 framework allowed H200 sales with revenue-sharing conditions, Chinese authorities initially hesitated to approve imports, complicating Nvidia’s market re-entry. Recent progress, including licenses for multiple customers and production restarts, indicates a thaw in cross-Pacific tensions. However, historical challenges—such as the 2025 ban on H20 processors in China and anti-monopoly investigations—highlight the fragility of this progress. Investors are likely weighing the risks of renewed regulatory friction against the potential for China to become a $50 billion AI chip market, as previously estimated by Nvidia.

In sum, Nvidia’s stock performance reflects a complex interplay of regulatory breakthroughs, strategic product adaptations, and robust financial fundamentals. While the China market re-entry offers a substantial growth avenue, the company must navigate evolving export controls and competitive pressures to fully capitalize on this opportunity. The coming quarters will be critical in determining whether this regulatory pivot translates into sustained revenue gains and justifies the strong analyst optimism.